News Exscientia builds cancer pipeline with two BMS drugs LSD1 and MALT1 inhibitors inherited from BMS alliance will be biotech's next cancer candidates.
News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
News Money held by SVB UK clients safe, thanks to HSBC HSBC steps forward to take over SVB's UK customers, protecting their deposits.
News Lilly shares disappointing A4 study results for solanezumab The drug only targets soluble amyloid beta-protein and doesn't clear amyloid plaques.
News AZ cancer drugs chalk up wins in early-stage lung cancer Tagrisso and Imfinzi show benefit as neoadjuvant and adjuvant therapy for patients with NSLC.
News Merck sets sights on Epstein-Barr virus jab with Opko deal Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.
News Lilly partners with Hims & Hers on obesity drug sales Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
